FDA clears Median Technologies’ lung nodule evaluation software
FDA approval for eyonis LCS was supported by data from Median’s RELIVE (NCT06751576) pivotal trial, which met its primary endpoint,...
clears
FDA clears RevealDX’s AI lung nodule diagnostic
RevealAI-Lung is now reimbursable in the US under the Medicare Outpatient Prospective Payment System (OPPS) at a rate of $650....
